New ADHD pill shows promise in early trial
NCT ID NCT05202327
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tested a new drug called PDC-1421 in 99 adults with ADHD to see if it can reduce symptoms like trouble focusing and hyperactivity. Participants took either the drug or a placebo for up to 8 weeks. The goal was to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cheng Hsin General Hospital
Taipei, 112, Taiwan
-
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 83301, Taiwan
-
Linkou chang Gung Memorial Hospital
Taoyuan, 33425, Taiwan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Taipei veterans General Hospital
Taipei, 112, Taiwan
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.